NO20023833D0 - Modifiserte cytokiner for anvendelse i cancerterapi - Google Patents

Modifiserte cytokiner for anvendelse i cancerterapi

Info

Publication number
NO20023833D0
NO20023833D0 NO20023833A NO20023833A NO20023833D0 NO 20023833 D0 NO20023833 D0 NO 20023833D0 NO 20023833 A NO20023833 A NO 20023833A NO 20023833 A NO20023833 A NO 20023833A NO 20023833 D0 NO20023833 D0 NO 20023833D0
Authority
NO
Norway
Prior art keywords
cancer therapy
modified cytokines
cytokines
modified
homing
Prior art date
Application number
NO20023833A
Other languages
English (en)
Other versions
NO330913B1 (no
NO20023833L (no
Inventor
Angelo Corti
Original Assignee
San Raffaele Centro Fond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by San Raffaele Centro Fond filed Critical San Raffaele Centro Fond
Publication of NO20023833D0 publication Critical patent/NO20023833D0/no
Publication of NO20023833L publication Critical patent/NO20023833L/no
Publication of NO330913B1 publication Critical patent/NO330913B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof
    • C08L89/04—Products derived from waste materials, e.g. horn, hoof or hair
    • C08L89/06—Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Birds (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
NO20023833A 2000-02-15 2002-08-13 Konjugeringsprodukt, dets anvendelse og farmasoytisk preparat inneholdende det samme. NO330913B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000MI000249A IT1317835B1 (it) 2000-02-15 2000-02-15 Citochine modificate per uso nella terapia del cancro.
PCT/EP2001/001543 WO2001061017A2 (en) 2000-02-15 2001-02-13 Modified cytokines for use in cancer therapy

Publications (3)

Publication Number Publication Date
NO20023833D0 true NO20023833D0 (no) 2002-08-13
NO20023833L NO20023833L (no) 2002-10-15
NO330913B1 NO330913B1 (no) 2011-08-15

Family

ID=11444017

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023833A NO330913B1 (no) 2000-02-15 2002-08-13 Konjugeringsprodukt, dets anvendelse og farmasoytisk preparat inneholdende det samme.

Country Status (29)

Country Link
US (4) US7150869B2 (no)
EP (2) EP2080804A1 (no)
JP (1) JP4836384B2 (no)
KR (1) KR100888761B1 (no)
CN (2) CN1446261B (no)
AT (1) ATE424461T1 (no)
AU (1) AU784173C (no)
BG (1) BG65931B1 (no)
BR (1) BR0108391A (no)
CA (1) CA2399986C (no)
CY (1) CY1109034T1 (no)
CZ (1) CZ299486B6 (no)
DE (1) DE60137835D1 (no)
DK (1) DK1255845T3 (no)
EA (1) EA007838B1 (no)
ES (1) ES2322234T3 (no)
HK (1) HK1048649B (no)
HU (1) HU227894B1 (no)
IL (2) IL150984A0 (no)
IT (1) IT1317835B1 (no)
MX (1) MXPA02007899A (no)
NO (1) NO330913B1 (no)
PL (1) PL207263B1 (no)
PT (1) PT1255845E (no)
SI (1) SI1255845T1 (no)
SK (1) SK287550B6 (no)
UA (1) UA85365C2 (no)
WO (1) WO2001061017A2 (no)
ZA (1) ZA200206450B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317835B1 (it) * 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
US7109303B2 (en) * 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
US7309694B2 (en) 2000-02-15 2007-12-18 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
WO2001062298A2 (en) 2000-02-24 2001-08-30 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
AU2006200762B2 (en) * 2000-02-24 2008-08-21 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
DE60316407T2 (de) 2002-02-06 2008-06-19 Ares Trading S.A. Tumornekrosefaktor in kombination mit interferon zur behandlung und/oder verhinderung einer demyelinisierenden krankheit
EP1346729A1 (en) * 2002-03-19 2003-09-24 Cardiovascular Research Institute Maastricht Targeting of myocardial angiogenesis through CD13/APN
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
EP1613344A2 (en) * 2003-03-31 2006-01-11 Greenville Hospital System Anti-tumor vasculature effects of human serum albumin derivatives
GB0312309D0 (en) * 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome
CA2593964A1 (en) 2004-12-23 2006-06-29 Molmed Spa Conjugation product
US7625555B2 (en) * 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
GB0803076D0 (en) * 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
WO2009138396A2 (en) * 2008-05-13 2009-11-19 Molmed S.P.A. Conjugates for the treatment of mesothelioma
CN108314741B (zh) * 2018-03-22 2021-08-03 中国人民解放军第四军医大学 一种肿瘤血管靶向抗癌肽nkl-dota及其制备方法
EP3882257A1 (en) 2020-03-20 2021-09-22 Ospedale San Raffaele S.r.l. Ngr conjugates and uses thereof
WO2023170209A1 (en) 2022-03-09 2023-09-14 Ospedale San Raffaele Srl Fusion proteins and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4863713A (en) 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5214131A (en) 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5091176A (en) 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
IT1245748B (it) 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5811512A (en) 1991-08-22 1998-09-22 The Trustees Of The University Of Pennsylvania Non-peptide peptidomimetics and related cyclic hexapeptides
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
DE69433343D1 (de) 1993-12-07 2003-12-24 Neorx Corp Pretargeting verfahren und mitteln
US5888814A (en) 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
US5891418A (en) 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
DE69734887T2 (de) * 1996-09-10 2006-08-24 The Burnham Institute, La Jolla Tumor findende moleküle, davon abstammende konjugate und verfahren zu deren verwendung
US6576239B1 (en) * 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6759509B1 (en) * 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
US6180084B1 (en) * 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
AU9477398A (en) * 1997-09-10 1999-03-29 Burnham Institute, The Methods of identifying molecules that home to angiogenic vasculature in tumors
IT1317835B1 (it) 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.

Also Published As

Publication number Publication date
CA2399986A1 (en) 2001-08-23
CN1446261A (zh) 2003-10-01
KR100888761B1 (ko) 2009-03-17
UA85365C2 (ru) 2009-01-26
HUP0300005A3 (en) 2005-09-28
AU784173B2 (en) 2006-02-16
WO2001061017A2 (en) 2001-08-23
CN1853730A (zh) 2006-11-01
AU784173C (en) 2006-09-07
DE60137835D1 (de) 2009-04-16
US7150869B2 (en) 2006-12-19
CY1109034T1 (el) 2014-07-02
CZ299486B6 (cs) 2008-08-13
HK1048649A1 (en) 2003-04-11
DK1255845T3 (da) 2009-06-22
CA2399986C (en) 2012-10-02
PL362670A1 (en) 2004-11-02
EP1255845B1 (en) 2009-03-04
SK11512002A3 (sk) 2003-02-04
CN1853730B (zh) 2013-07-24
US7476721B2 (en) 2009-01-13
AU4413501A (en) 2001-08-27
SK287550B6 (sk) 2011-01-04
IL150984A (en) 2011-04-28
NO330913B1 (no) 2011-08-15
EA200200808A1 (ru) 2003-02-27
HK1048649B (zh) 2009-08-14
JP2004520801A (ja) 2004-07-15
MXPA02007899A (es) 2004-09-10
BG65931B1 (bg) 2010-05-31
HU227894B1 (en) 2012-05-29
BR0108391A (pt) 2003-03-11
EP2080804A1 (en) 2009-07-22
PL207263B1 (pl) 2010-11-30
PT1255845E (pt) 2009-04-09
US20100196458A1 (en) 2010-08-05
US20050265965A1 (en) 2005-12-01
ATE424461T1 (de) 2009-03-15
ITMI20000249A1 (it) 2001-08-15
IT1317835B1 (it) 2003-07-15
ES2322234T3 (es) 2009-06-18
IL150984A0 (en) 2003-02-12
EP1255845A2 (en) 2002-11-13
HUP0300005A2 (hu) 2003-04-28
JP4836384B2 (ja) 2011-12-14
NO20023833L (no) 2002-10-15
US7622556B2 (en) 2009-11-24
CN1446261B (zh) 2010-05-05
CZ20023093A3 (cs) 2003-02-12
SI1255845T1 (sl) 2009-08-31
KR20020089348A (ko) 2002-11-29
EA007838B1 (ru) 2007-02-27
ITMI20000249A0 (it) 2000-02-15
US20070041939A1 (en) 2007-02-22
US20030157055A1 (en) 2003-08-21
ZA200206450B (en) 2003-04-24
WO2001061017A3 (en) 2002-01-31
BG106999A (bg) 2003-04-30

Similar Documents

Publication Publication Date Title
NO20023833D0 (no) Modifiserte cytokiner for anvendelse i cancerterapi
ATE320435T1 (de) Oxazolo-, thiazolo- und selenazolo-(4,5- c)naphthyridin-4-amine und analoge davon
GEP20074091B (en) Cripto blocking antibodies and uses thereof
BR0211769A (pt) Combinações antineoplásicas
EA200300375A1 (ru) Производные 2-амино-2-алкил-4-гексеновой и -гексиновой кислот, которые могут быть использованы в качестве ингибиторов синтетазы оксида азота
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
TR199902818T2 (xx) Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler.
TW200612918A (en) Lonidamine analogs
TR200102308T2 (tr) Yüzey etkinliğine sahip yapay peptidler ve bunların yapay yüzey aktif maddelerin hazırlanmasında kullanımı
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
DK0774005T3 (da) Overfladeudtrykkelse af enzymer i genorienteret prodrug-terapi
MY138883A (en) Use of asiatic acid for treatment of cencer
SE9904377D0 (sv) Pharmaceutical combinations
NO20031860D0 (no) Kahalaolid F
DE602005021681D1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
WO2004041297A3 (en) Modified cytokines for use in cancer therapy
EP1364657A4 (en) REMEDIES AGAINST TUMORS AFFECTING HEMATOPOIETIC BODIES
HUP0204208A2 (hu) Pruritus kezelésére szolgáló külsőleges gyógyszerkészítmény
HK1079116A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
TR200302193T4 (tr) Kombinasyon kemoterapisi.
DE60141169D1 (de) Verwendung einer zusammensetzung mit n-acetylcystein zur konditionierung von stammzellen
GB9723824D0 (en) Cytostatic agents
CY1114651T1 (el) Φαρμακευτικο σκευασμα που περιλαμβανει β-καρβολινη και η χρηση του για τη θεραπεια της σεξουαλικης δυσλειτουργιας
DE50211461D1 (de) Pharmazeutische zusammensetzung enthaltend bulbophyllum

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees